Evotec SE (EVO) Beginning Cash Balance (2009 - 2022)
Evotec SE's (EVO) quarterly Beginning Cash Balance came in at $705112.5 in Q3 2022, up 41.49% year-over-year from $498343.2 in Q3 2021, and down 5.51% quarter-over-quarter from $746220.5 in Q2 2022.
Powered by 
Analysis
Evotec SE (EVO) Beginning Cash Balance (2009 - 2022) Analysis & Trends
Evotec SE has disclosed Beginning Cash Balance across 3 years of filings, most recently posting $705112.5 for Q3 2022.
- In Q3 2022, Beginning Cash Balance rose 41.49% year-over-year to $705112.5; the TTM figure through Sep 2022 stood at $705112.5 (up 41.49% YoY), while the FY2009 annual figure was $76.8 million, changed N/A from the prior year.
- Beginning Cash Balance came in at $705112.5 for Q3 2022 at Evotec SE, down from $746220.5 in the prior quarter.
- In the past five years, Beginning Cash Balance ranged from a high of $784879.9 in Q1 2022 to a low of $498343.2 in Q3 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2022 | 705,112.45 |
| Jun 30, 2022 | 746,220.49 |
| Mar 31, 2022 | 784,879.95 |
| Sep 30, 2021 | 498,343.24 |
| Jun 30, 2021 | 508,901.02 |
| Mar 31, 2021 | 509,731.26 |
| Dec 31, 2009 | 81.31 Mn |